The Operational Architect: Headwater Science Taps Barnes to Scale Evidence

DURHAM, N.C. – June 23, 2026 – Headwater Science, a company at the sharp end of healthcare data analysis, recently announced the appointment of Susan Barnes, Ph.D., as its new head of operations. On the surface, it’s a standard corporate announcement. But for those watching the evolution of real-world evidence (RWE), this move is a significant tell. It signals a critical maturation point for the industry: the moment when brilliant science must be paired with ironclad operational discipline to achieve scale and true market impact.

Barnes is not just another executive. She joins Headwater from senior leadership roles at industry giants Parexel and IQVIA, where her focus was on large-scale transformation and driving global data strategies centered on AI and operational efficiency. Headwater Science, the firm formerly known as NoviSci, is betting that this specific expertise is the key to unlocking the next phase of its growth. Her appointment is less about maintaining the status quo and more about architecting the future.

The Imperative for Operational Rigor

To understand the significance of this hire, one must first appreciate the unique space Headwater Science occupies. The company doesn’t just analyze data; it specializes in “principled, reproducible evidence generation” and builds “regulatory-grade analytical software.” This is the high-stakes end of the data science pool, where the outputs are expected to withstand the intense scrutiny of bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

For years, the promise of RWE has been percolating. Now, regulators are formalizing its use, issuing guidance on how data from electronic health records and medical claims can inform decisions on drug effectiveness, not just safety. This has created a surge in demand for evidence that is not only insightful but also transparent, auditable, and reproducible. A one-off academic study won't cut it; life sciences companies need an “evidence-generation engine.”

This is where operations become paramount. Creating regulatory-grade evidence requires more than a clever algorithm. It demands standardized data pipelines, meticulous version control, validated software, and unimpeachable governance—all executed flawlessly, every time. As one industry analyst noted, “The transition from bespoke data projects to a scalable, factory-like production of evidence is the single biggest challenge for RWE firms today.” Headwater is placing a strategic bet that Barnes is the architect to design and run that factory.

An Architect of Scale and Efficiency

Barnes's resume reads like a blueprint for building such an operation. At Parexel, she was Vice President of Clinical and Commercial Business Technology Solutions, helping to craft a global strategy focused on AI. Before that, she spent nearly a decade at IQVIA, where, as Head of Strategic and Business Operations for IQVIA Biotech, she led initiatives that generated significant operational savings and improved global performance. Her background is not in pure epidemiology, but in the systems that allow science to scale.

Her Ph.D. in Materials Science and Engineering, combined with a Master of Project Management and a Lean Six Sigma Master Black Belt certification, paints a picture of a leader who understands both deep science and process discipline. This unique combination is precisely what a company like Headwater needs. As President Alan Brookhart stated in the announcement, “Susan has spent her career helping complex healthcare organizations scale and deliver results. She combines strategic vision with operational discipline and a proven ability to lead.”

Her recent recognition with the 2024 Healthcare Businesswomen's Association Rising Star Award for transformational leadership further validates her reputation as an innovator in a field often bogged down by legacy processes. She is being brought in not just to manage but to transform.

A Key Move in Highlander Health’s Grand Plan

The context for this appointment extends beyond Headwater itself, reaching up to its parent company, Highlander Health. Launched in 2024 by industry luminaries Amy Abernethy (a former FDA Principal Deputy Commissioner) and Brad Hirsch, Highlander Health has an ambitious mission: to accelerate the path to personalized healthcare by fundamentally improving clinical evidence generation. Headwater Science, along with its sister company Pedestal Health, was one of Highlander's inaugural investments, hand-picked to be the “methodological and analytical engine” for this vision.

Highlander’s strategy is to bridge the gap between life sciences and providers, creating a continuous loop of evidence generation that can reduce drug development timelines and personalize care. This grand plan hinges on the ability of its portfolio companies to deliver. By installing a high-caliber operational leader like Barnes, Highlander is ensuring its core scientific asset has the industrial-strength foundation needed to execute on this vision at scale. Barnes's role is to ensure the engine doesn't just run, but that it can be supercharged without breaking down.

In her own words, Barnes expressed excitement about joining “at such a pivotal moment.” She added, “I look forward to strengthening our operational foundation and driving continued growth.” This statement, while standard for a press release, carries immense weight in this context. The “operational foundation” is everything. It’s the framework that will allow Headwater’s deep expertise in causal inference and regulatory methods to move from a specialized service to a market-defining platform, fulfilling its crucial role in Highlander Health's broader campaign to reshape modern medicine.